Deaths in cancer trials remain mystery for promising therapy

December 04, 2016

CAR t-cell

The experimental CAR T-cell immunotherapy has shown dramatic results, including long-term cures, for cancer patients with severe disease, but has also left puzzling questions about deaths that have occurred during some tests, Bloomberg reports in a story published by The Washington Post.

“It’s a double-edged sword,” Lewis Silverman, clinical director of Dana-Farber/Boston Children’s Hematologic Malignancy Center, tells Bloomberg. “You have to get through some bad side effects because that’s actually a sign that the CAR-T is doing something.”

  • Read the story. Other outlets that picked up the story include the Chicago Tribune and News OK (The Oklahoman).

Media Inquiries

Irene Sege
Senior Media Relations Specialist
irene.sege@childrens.harvard.edu
1-617-919-7379

Follow Us!

Stay updated on our latest news and developments by following us on Twitter.

Twitter Logo